BILIX
Bilix produces anti-inflammatory and cancer therapy drugs for inflammatory diseases.
BILIX
Social Links:
Industry:
Biotechnology Pharmaceutical
Address:
Yongsin, Kyonggi-do, South Korea
Country:
South Korea
Website Url:
http://www.bilix.com
Total Employee:
1+
Status:
Active
Contact:
+82 31 212 0961
Technology used in webpage:
Person Schema Gravatar Profiles CrUX Top 50m CrUX Dataset Google Translate Widget GTranslate.io
Similar Organizations
Ascarit
Ascarit provides nutritious and pharmaceutical products for metabolic diseases.
Keymed Biosciences
Keymed Biosciences develops innovative monoclonal antibody drugs and other therapeutic protein drugs for major diseases.
Merck
Merck is a biopharmaceutical company that offers medicines and vaccines for various diseases.
PRD Therapeutics
PRD Therapeutics is a pharmaceutical company that develops medicines for different metabolic diseases.
Yoda Pharmaceuticals
Yoda Pharmaceuticals utilizes AI technology to develop pharmaceutical drugs for neuropsychological and neurological diseases.
Investors List
Alpenroute Asset Management
Alpenroute Asset Management investment in Venture Round - Bilix
Official Site Inspections
http://www.bilix.com
- Host name: 92.116.168.184.host.secureserver.net
- IP address: 184.168.116.92
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
More informations about "Bilix"
Bilix - 빌릭스 | Bilix
May 21, 2020 Bilix is established based on the world’s first PEGylated bilirubin platform technology to produce numerous “First in Class” in anti-inflammatory and “Best in Class” in cancer therapy drugs in addition to achieving other business …See details»
Overview - 빌릭스 | Bilix
May 25, 2020 We are a biotech company founded in 2018 based on the world’s first PEGylated bilirubin platform technology. Our headquarter is located in Seoul, South Korea.Read More →See details»
Bilix - Crunchbase Company Profile & Funding
Who invested in Bilix? Bilix is funded by Alpenroute Asset Management. When was the last funding round for Bilix? Bilix closed its last funding round on Jan 1, 2019 from a Venture - …See details»
Leadership - 빌릭스 | Bilix
May 25, 2020 Myung L. Kim, Ph.D., MBA Founder and Chief Executive Officer CTO & COO, Eutilex (KOSDAQ listed) CEO & Board of Directors, NanoEnTek (KOSDAQ listed) Senior Vice …See details»
Bilix Company Profile 2024: Valuation, Funding
Information on valuation, funding, cap tables, investors, and executives for Bilix. Use the PitchBook Platform to explore the full profile.See details»
Bilix Co., Ltd.: Drug pipelines, Patents, Clinical trials - Synapse
Nov 7, 2023 Explore Bilix Co., Ltd. with its drug pipeline, therapeutic area, technology platform, 1 clinical trial, Technology Platform:Small molecule drug, Drug:BX-001N.See details»
Bilix - Funding, Financials, Valuation & Investors - Crunchbase
Jan 1, 2019 Bilix produces anti-inflammatory and cancer therapy drugs for inflammatory diseases.See details»
Bilix - Overview, News & Similar companies | ZoomInfo.com
View Bilix (www.bilix.com) location in Gyeonggi, South Korea , revenue, industry and description. Find related and similar companies as well as employees by title and much more.See details»
Bilix - Tech Stack, Apps, Patents & Trademarks - Crunchbase
The intellectual property of Bilix includes 8 registered patents primarily in the ' Medical Or Veterinary Science; Hygiene ' category, according to IPqwery. Additionally, Bilix has registered …See details»
Bilix Co., Ltd.: 药物管线_专利_临床试验_投融营收
了解Bilix Co., Ltd.公司的药物管线，治疗领域，技术平台，以及它的1项临床试，技术平台:小分子化药，药物:BX-001N。See details»
Mission & Vision - 빌릭스 | Bilix
May 25, 2020 Mission Our mission is to improve health of mankind one patient at a time for better and longer life. Vision Finding a new cure for incurable diseases requires courage to take on insurmountable challenges. All …See details»
Bilix - VentureRadar
"Bilix is established based on the world’s first PEGylated bilirubin platform technology to produce numerous “First in Class” in anti-inflammatory and “Best in Class” in cancer therapy drugs in …See details»
BX-001N - Drug Targets, Indications, Patents - Synapse - Patsnap
BX-001N, Initially developed by Bilix Co., Ltd., Now, its global highest R&D status is Phase 1, Therapeutic Areas: Cardiovascular Diseases,Other Diseases, Active ...See details»
Bilix - Products, Competitors, Financials, Employees, Headquarters ...
Bilix has achieved notable milestones, including over 20 scientific publications, successful pre-clinical trials, and partnerships with leading Korean cosmetic companies. By the end of 2024, …See details»
Bilix
Bilix is established based on the world’s first PEGylated bilirubin platform technology to produce numerous “First in Class” and “Best in Class” anti-inflammatory and cancer therapy drugs in …See details»
Bilix - Crunchbase
Bilix produces anti-inflammatory and cancer therapy drugs for inflammatory diseases.See details»
Bilix | Login
Login to your Account Email Password RememberForgot Password ?See details»
Bilix: Korean Biotech Startup Unveils Breakthrough PEGylated …
Jul 31, 2024 Bilix, a pioneering Korean biotech startup, is capturing global attention with its revolutionary PEGylated bilirubin technology. Known as Brixelle®, this cutting-edge platform …See details»
Bilix: Korean Biotech Startup Unveils Breakthrough PEGylated …
Jul 23, 2024 Bilix, a pioneering Korean biotech startup, is capturing global attention with its revolutionary PEGylated bilirubin technology. Known as Brixelle®, this cutting-edge platform …See details»
Bilix: Avant-Garde Therapy for Intractable Diseases
Oct 4, 2023 To address the limitations imposed by FDA guidelines, Bilix successfully developed a proprietary technology for the chemical synthesis of bilirubin. This breakthrough enables …See details»